Etizolam
| Clinical data | |
|---|---|
| Trade names | Etizest, Etilaam, Etizex, Depas, Sedekopan, Pasaden |
| Dependence liability | Moderate |
| Routes of administration | Oral, sublingual, rectal |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 93% |
| Metabolism | Hepatic |
| Elimination half-life | 3.4 hours (main metabolite is 8.2 hours) |
| Duration of action | 5-7 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.188.773 |
| Chemical and physical data | |
| Formula | C17H15ClN4S |
| Molar mass | 342.85 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Etizolam (marketed under numerous brand names) is a thienodiazepine derivative which is a benzodiazepine analog. The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring and triazole ring has been fused, making the drug a thienotriazolodiazepine.
Although a thienodiazepine, etizolam is clinically regarded as a benzodiazepine because of its mode of action via the benzodiazepine receptor and directly targeting GABAA allosteric modulator receptors.
It possesses anxiolytic, amnesic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.
It was patented in 1972 and first approved for medical use in Japan in 1984.
As of April 2021, the export of etizolam has been banned in India.